Pharma Mar, S.A. (OTCMKTS:PHMMF – Get Rating) was the recipient of a significant increase in short interest in April. As of April 15th, there was short interest totalling 1,500 shares, an increase of 200.0% from the March 31st total of 500 shares. Based on an average daily trading volume, of 100 shares, the short-interest ratio is currently 15.0 days.
Separately, Zacks Investment Research downgraded shares of Pharma Mar from a “hold” rating to a “strong sell” rating in a research note on Wednesday, March 9th.
Shares of OTCMKTS PHMMF opened at $77.00 on Thursday. The firm’s 50 day moving average price is $66.21 and its 200-day moving average price is $67.01. Pharma Mar has a 52-week low of $55.47 and a 52-week high of $124.70.
Pharma Mar, SA, a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference.
- Get a free copy of the StockNews.com research report on Pharma Mar (PHMMF)
- Automatic Data Processing Is Ready To Scale New Heights
- Xerox Holdings Stock is a Value Play
- Carl Icahn Buys More Xerox
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
Receive News & Ratings for Pharma Mar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharma Mar and related companies with MarketBeat.com's FREE daily email newsletter.